NCT02339571
|
Phase II |
Sargramostim
Nivolumab
Ipilimumab
|
Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery |
Suspended |
NCT00621036
|
Phase II |
Methotrexate
Thiotepa
Sargramostim
|
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma |
Withdrawn |
NCT03761914
|
Phase Ib/II |
Galinpepimut-S
Galinpepimut-S + Pembrolizumab
Pembrolizumab
Sargramostim
|
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers |
Recruiting |
NCT01827137
|
Phase I |
WT1 vaccine
Lenalidomide
Sargramostim
|
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation |
Unknown status |
NCT01265433
|
Phase II |
Sargramostim
WT1 vaccine
|
Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy |
Completed |
NCT01479244
|
Phase III |
E75
Sargramostim
|
Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence |
Completed |
NCT01857934
|
Phase II |
Doxorubicin
Sargramostim
Aldesleukin
Vincristine
Filgrastim
Tretinoin
Levetiracetam
Cisplatin + Etoposide
Hu14.18K322A
Busulfan + Melphalan
Cyclophosphamide + Topotecan
|
Therapy for Children With Advanced Stage Neuroblastoma |
Recruiting |
NCT02411786
|
Phase I |
pTVG-AR
Sargramostim
|
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF |
Active, not recruiting |
NCT02510950
|
Phase I |
Sargramostim
poly ICLC
Temozolomide
|
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma |
Terminated |
NCT01570036
|
Phase II |
E75
Sargramostim
Trastuzumab
|
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax |
Completed |
NCT01890980
|
Phase II |
WT1 vaccine
Sargramostim
|
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 |
Active, not recruiting |
NCT01530984
|
Phase II |
Sargramostim
Ipilimumab
|
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer |
Withdrawn |
NCT01903330
|
Phase II |
Bevacizumab
Cyclophosphamide
Sargramostim
|
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme |
Recruiting |
NCT02009397
|
Phase Ib/II |
Sargramostim
Ipilimumab
|
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients |
Unknown status |
NCT02636582
|
Phase II |
Sargramostim
Nelipepimut-S Plus GM-CSF
|
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer |
Recruiting |
NCT02620865
|
Phase Ib/II |
Paclitaxel
Aldesleukin
Oxaliplatin
Sargramostim
Gemcitabine
Fluorouracil + Leucovorin
|
Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Active, not recruiting |
NCT03126916
|
Phase III |
Doxorubicin
131I-MIBG
Sargramostim
Etoposide
Melphalan
Busulfan
Isotretinoin
Vincristine
Cisplatin
Cyclophosphamide
Thiotepa
Crizotinib
dexrazoxane
Carboplatin
Aldesleukin
Topotecan
Dinutuximab
|
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma |
Recruiting |
NCT02297698
|
Phase II |
Sargramostim
Trastuzumab
E75
|
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients |
Active, not recruiting |